Navigation Links
UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts
Date:6/12/2009

n cancers; and
  • Nitrogen runoff in bays and coastal areas, where it makes algae numbers spike then crash, drawing oxygen from the water and leading to "dead zones" -- areas that cannot support finfish, shellfish or most other aquatic life.

    Those environmental impacts are not fully documented, Tomich said.

    "With this new funding, we can start to fill in those blanks, and improve management of nitrogen, carbon and water to help move agriculture toward sustainability in significant ways," he said.

    Data on agricultural nitrogen pollution are limited, and some nitrogen pollution forms are difficult to monitor. Measurements can be labor-intensive and expensive and are influenced by variables such as weather conditions, irrigation timing and method, and crop-specific fertilization practices.

    The new studies should improve data-collection methods, said Agricultural Sustainability Institute researcher Johan Six, a professor in the Department of Plant Sciences.

    "It's urgent that we know how much nitrous oxide and other greenhouse gases are released during irrigation and fertilization of farm lands in California," Six said. "The good news is we know that it is economically feasible to reduce these emissions. The first step is quantifying the necessary reductions."

    The new Agricultural Sustainability Institute grants and objectives include:

    • $1.5 million from the David and Lucile Packard Foundation for a statewide assessment of existing scientific evidence on nitrogen use in conventional and alternative farming systems, and relevant practices and policy options. Also: a program to improve communication about nitrogen concerns among California farmers, ranchers, extension advisors, environmental and community groups, agribusiness (including the fertilizer industry) and government agencies (including California Department of Food and Agriculture and U.S. Environmental Protection Agency). This grant
      '/>"/>

    Contact: Tom Tomich
    tptomich@ucdavis.edu
    530-574-2503
    University of California - Davis
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. UC Davis bird-flu expert calls for changes in early-warning system
    2. UC Davis researchers discover how HIV turns food-poisoning into lethal infection
    3. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
    4. UC Davis researcher leads climate-change discovery
    5. UC Davis researchers define characteristics, treatment options for XXYY syndrome
    6. UC Davis researchers discover new drug target for inflammatory disease
    7. UC Davis chemical ecologist wins major award
    8. UC Davis researchers discover a key to aggressive breast cancer
    9. UC Davis researchers discover Achilles heel in pancreatic cancer
    10. UC Davis researchers exploring gene therapy to fight AIDS
    11. UC Davis team refines cancer treatments to reduce potential nerve damage
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
    (Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
    (Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
    Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Ministerial Roundtable Discusses Future of Medical Tourism 62455 1Ministerial Roundtable Discusses Future of Medical Tourism 62455 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4Neil H Ekblom and Medical Malpractice Defense Team Join LeClairRyan 6686 1Neil H Ekblom and Medical Malpractice Defense Team Join LeClairRyan 6686 2Neil H Ekblom and Medical Malpractice Defense Team Join LeClairRyan 6686 3
    ...e isolated a new peptide antibiotic from the Ameri... many diseases in oysters. , The new antimicrobial...ect against bacteria in Crassostrea virginica, a s...ant economically to Atlantic and Gulf Coast fisher...disease-resistant oysters for aquaculture and fish...
    ...e Department of Energy,s Lawrence Berkeley Nationa...ct tens of thousands of high-quality images of bio...y and automatically, with accuracy approaching tha...thm, described as "particle picking by segmentatio...er of methods for determining biological structure...
    ...c. 4 as an advance online publication of the journ...have virtually no activity in a key part of the br...erving emotions. , Mirror neurons fire when a pers... she observes the same action performed by others....n matching system provides a neural mechanism by w...
    Other Biology News:Picking particles faster than one at a time 2Picking particles faster than one at a time 3Picking particles faster than one at a time 4Picking particles faster than one at a time 5UCLA imaging study of children with autism finds broken mirror neuron system 2
    (Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
    (Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
    (Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
    (Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
    Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
    ...d., Nov. 4 PharmAthene, Inc.,(NYSE Alternext US: ...ermeasures against biological and chemical threats...and Chief Executive Officer of PharmAthene,will pr...care Conference in,New York on Wednesday, November...s II Room (4th Floor) at The New York Palace Hotel...
    ...celand, November 4 deCODE,genetics (Nasdaq: DCGN ...aring before a Nasdaq Listing Qualifications Panel...asdaq Marketplace Rule 4450(b)(1)(A), which,requir...$50 million. On,October 31, 2008, deCODE received ... Market LLC indicating that the Company had not re...
    ...d., Nov. 4 Novavax, Inc. (Nasdaq:,NVAX) today ann...financial,results in a press release to be issued ... The Company will hold an investor conference call...stern Time on November 10,2008. The call will be h...icer Dr. Rahul Singhvi and other members of senior...
    Other Biology Technology:deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 2deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 3deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 4Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call 2
    Human Serum (All Male Donors) from Irvine Scientific
    Human Serum Type AB from Irvine Scientific
    Senescence Colorimetric Assay Kit from BioVision
    Rabbit Anti-Human TARDBP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
    Biology Products: